See the DrugPatentWatch profile for cosentyx
What patents cover Cosentyx (secukinumab) and who holds them?
Novartis develops and markets Cosentyx (secukinumab), a biologic for autoimmune diseases. However, there is no single “Cosentyx patent” that covers the whole product globally. Coverage typically comes from a bundle of patents held by Novartis affiliates (and sometimes related entities) that can differ by country and by the specific aspect they protect, such as the active ingredient, formulations, manufacturing processes, and method-of-use claims.
Because the exact patent numbers and claims depend on the jurisdiction (US, EU, UK, Japan, etc.), the most practical way to identify “the” relevant patents for your location is to check the local patent registry and any supplementary protection records (like patent term extensions/exclusivity where applicable).
How long does Cosentyx patent protection last (and when does exclusivity end)?
Patent protection timelines for biologics are driven by multiple, overlapping terms:
- the final scheduled expiration of the underlying patents covering secukinumab,
- possible extensions (where the country allows them), and
- regulatory exclusivity periods for biologics (which can delay approval of certain follow-on products even if some patents expire).
As a result, “when Cosentyx exclusivity ends” can mean different dates depending on whether you mean patent expiry, regulatory exclusivity, or the first date a biosimilar is authorized in a specific country.
If you tell me the country (for example, US vs EU vs UK) and whether you mean patents or biosimilar approval, I can narrow the answer to the correct concept and timing.
Are biosimilars of Cosentyx allowed to enter while patents are still active?
Biosimilars generally can’t freely launch just because some patents expire; they face a combination of:
- patent litigation or “patent dance”/exchange procedures in some jurisdictions, and
- approval and exclusivity rules in regulators’ processes.
If a biosimilar developer challenges particular patents (or argues they’re invalid or not infringed), courts can decide which patents block launch, and the launch date can shift based on outcomes.
Which countries are most relevant for Cosentyx patent schedules?
Cosentyx is sold in many markets, and the applicable patent list and expiration dates differ widely. In practice, people track:
- the United States (FDA-regulated pathway and patent listing practices),
- the European Union (national patents plus EU-level frameworks like SPCs in some cases), and
- the UK (UK patent/exclusivity mechanics).
What matters most if you’re researching Cosentyx patents for a biosimilar or investment thesis?
You usually care about:
- the specific patents that still have remaining life in the target market,
- whether those patents cover the molecule itself versus formulations/processes versus methods of use,
- whether patents are being asserted in litigation,
- and whether there are regulatory exclusivity periods that extend beyond the “plain” patent expiry.
If you share your target market and goal (academic research, biosimilar monitoring, or general curiosity), I can help map the right approach and what dates to look for.
Quick questions to get you an accurate answer
1) Which country’s Cosentyx patents do you mean (US, EU, UK, etc.)?
2) Do you want the exact patent numbers/expiration dates, or just the practical “latest exclusivity/launch blocker” timeline?
3) Are you asking about biosimilar entry in particular?
Sources
None provided.